A Promising Chemotherapy Agent, Gd@C82(OH)22

transcript

Tianjin Medical University Cancer Institute & Hospital

Research

ter for C

ancer N

Research

ter for C

ancer N

A Promising Chemotherapy Agent, Gd@C82(OH)22

Ning ZhangTianjin Medical University Cancer Institute and Hospital

UICC 2008

Research

ter for C

ancer N

Research

ter for C

ancer N

Chemotherapies have always been

accompanied with serious side effects.

Can nanoparticles provide a new approach to

design low toxic therapeutic agents?

Research

ter for C

ancer N

Research

ter for C

ancer N

Treatments with Gd@C82(OH)22 Inhibit hepatoma growth in a mouse model

Nano Lett Vol 5, pg 2050 Gd@C82(OH)22 inhibits tumor growth in a breast tumor model.

0.28 mg/kg1.20mg/kg

Research

ter for C

ancer N

Research

ter for C

ancer N

Gd@C82(OH)22 doesn’t show cytotoxicity

Research

ter for C

ancer N

Research

ter for C

ancer N

Treatments with Gd@C82(OH)22 reduced blood supply to tumors

Research

ter for C

ancer N

Research

ter for C

ancer N

Treatments with Gd@C82(OH)22 reduced blood vessel density

Research

ter for C

ancer N

Research

ter for C

ancer N

Treatments with Gd@C82(OH)22 induced a massive leukocyte infiltration in tumors.

Research

ter for C

ancer N

Research

ter for C

ancer N

Gd@C82(OH)22 induced iDC maturation and TH-1 response.

Research

ter for C

ancer N

Research

ter for C

ancer N

TreatmentsMetastasis

Salineq.d. ×20 day

C60(C(COOH)2)2

(0.4 mg/kg, n = 10)

C60(OH)20 (0.4

mg/kg, n = 10)38.0%

Gd@C82(OH)22 ，0.35mg/kg

q.d. ×20 day4.3 %

Treatments with Gd@C82(OH)22 cancer cell chemotaxis and metastasis

Research

ter for C

ancer N

Research

ter for C

ancer N

Summary

1. Treatment with Gd@C82(OH)22 inhibits tumor growth without detectable toxicity.

2. Gd@C82(OH)22 doesn’t show cytotoxicity.

3. Gd@C82(OH)22 inhibits blood supply to tumor tissues.

4. Gd@C82(OH)22 induced tumor immunity.

5. Gd@C82(OH)22 inhibits cancer cell chemotaxis

Blood supply

Tumor immunity

Metastasis

Research

ter for C

ancer N

Research

ter for C

ancer N

Chinese AcademyInstitute of High Energy

Physics

Tianjin Cancer Institute and

Hospital

Research Center for Cancer Nanotechnology

National Center of Nanotechnology

Research

ter for C

ancer N

Research

ter for C

ancer N

Acknowledgements

Nanosafety Lab, Chinese Academy of ScienceDr. Yuliang Zhao, DirectorDr. Gengmei XingHuan Meng

Laboratory of Molecular Immunoregulation, NCIDr. Joost Oppenheim, ChiefDr. De Yang

Dr. Yujie MaDr. Guoguang YingDr. Ruifang Niu

Research

ter for C

ancer N

Research

ter for C

ancer N

Gd@C82(OH)22 induced a dendritic cell maturation

Research

ter for C

ancer N

Research

ter for C

ancer N

HR (100 ug/ml)-treated DCs migrated to SLC but not Rantes, suggesting the HR-treated DCs were mature DCs.

Gd@C82(OH)22 induced a dendritic cell to express CCR7 receptors

Research

ter for C

ancer N

Research

ter for C

ancer N

T cell cytokine production in response to Gd@C82(OH)22 -treated DCs

Research

ter for C

ancer N

Research

ter for C

ancer N

Treatments with Gd@C82(OH)22 disrupted the integrity of capillary blood vessels in tumors.

A Promising Chemotherapy Agent, Gd@C82(OH)22

Documents